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ABSTRACT 
This study is an effort to develop a tool for early detection of pancreatic cancer using 
evidential reasoning. An evidential reasoning model predicts the likelihood of an 
individual developing pancreatic cancer by processing the outputs of a Support 
Vector Classifier, and other input factors such as smoking history, drinking history, 
sequencing reads, biopsy location, family and personal health history. Certain 
features of the genomic data along with the mutated gene sequence of pancreatic 
cancer patients was obtained from the National Cancer Institute (NIH) Genomic 
Data Commons (GDC). This data was used to train the SVC. A prediction accuracy 
of ~85% with a ROC AUC of 83.4% was achieved. Synthetic data was assembled 
in different combinations to evaluate the working of evidential reasoning model.  
Using this, variations in the belief interval of developing pancreatic cancer are 
observed. When the model is provided with an input of high smoking history and 
family history of cancer, an increase in the evidential reasoning interval in belief of 
pancreatic cancer and support in the machine learning model prediction is observed. 
Likewise, decrease in the quantity of genetic material and an irregularity in the 
cellular structure near the pancreas increases support in the machine learning 
classifier’s prediction of having pancreatic cancer.  This evidence-based approach is 
an attempt to diagnose the pancreatic cancer at a premalignant stage. Future work 
includes using the real sequencing reads as well as accurate habits and real medical 
and family history of individuals to increase the efficiency of the evidential 
reasoning model. Next steps also involve trying out different machine learning 
models to observe their performance on the dataset considered in this study. 
 
Key Words: Pancreatic Cancer, Evidential Reasoning, Next Generation Sequencing, 
Genetic Mutations, Machine Learning, Support Vector Classifier, Biomarkers.  
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INTRODUCTION 
 
Pancreatic cancer is belligerent in its own way, since it hardly displays any 
observable symptoms before metastasis. Due to this, it is difficult to treat it before it 
spreads beyond control. The lone remedial option is the surgical resection of the 
tumor (Amin & DiMaio, 2016). The fact that it is fourth in position to cause cancer 
associated deaths reflects the lethality of this disease (Amin & DiMaio, 2016). 
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive types of 
pancreatic cancer in which cancerous tumors develop in the ductal cells of the 
pancreas. Tumors are accountable to certain genetic mutations occurring in the cells 
nearing pancreas. Several other factors such as smoking and drinking habits, a 
history of cancer in the family, and other hereditary factors may lead to aberrant 
mutation of these cells (See Appendix A for more information on these factors). 
PDAC is not only the most common pancreatic cancer, but also the deadliest one. 
The rate of a patient surviving beyond 5 years after being diagnosed with PDAC is 
as low as 7% (Gharibi, et al., 2017). This is because the PDAC is very difficult to 
detect at an early stage.  
The statistics of the pancreatic cancer cases resulting in death is brutal with an 
estimate of 83% cases leading to death. (Siegel, Miller, & Jemal, 2015). Gender 
wise, pancreatic cancer is observed to be a little more prevalent in males than in 
females: 13.9 out of 100,000 for males and 10.9 per 100,000 for females. Ethnicity 
wise, African Americans are at a higher risk of developing pancreatic cancer with 
probability of almost 15.8 out of 100,000 than that of Asian Americans which is 9.8 
out of 100,000 (Howlader, et al., 2016). More age may mean greater likelihood of 
developing pancreatic cancer. About 27% of new diagnoses belong to the age group 
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of 75 and 84 and 9% are in the age group of 45 and 54 years old (Howlader, et al., 
2016). 
PDAC is usually diagnosed at an advanced stage when the tumor has spread beyond 
the pancreatic region of the patient. At this point, it is hard to remove the tumor 
through surgery (Amin & DiMaio, 2016). As per the study by Gharibi, Adamian, 
and Kelber, due to its aggressive nature, PDAC metastasizes rapidly and the 
treatment of PDAC becomes extremely challenging (Gharibi, Adamian, & Kelber, 
2016). The 5-year survival rate decreases rapidly when PDAC is detected at an 
advanced stage. Therefore, there is a need to detect the pancreatic cancer at a 
primitive stage when it is localized to pancreas in order to treat it successfully (Amin 
& DiMaio, 2016).  
The limitation with existing methods to detect PDAC are that they fail in detecting 
the disease at a premalignant stage. Since pancreatic cancer causes genetic 
alterations, monitoring the presence of biomarkers in a tumor specimen remains a 
popular technique. But the attempts made to detect the presence of pre-malignant 
tumors by observing the genetic mutations in the patient’s tissue focus on limited 
genetic material. Research has found that there are about 63 different genes that get 
altered by pancreatic cancer (Gharibi, et al., 2017). Each of these genes may undergo 
multiple kinds of mutations, but an effective technique to predict the likelihood of 
pancreatic cancer by considering all genetic alterations as well as other factors such 
as smoking and drinking history, medical history, cellular structure, and others does 
not exist. Hence, there is a need to develop a technique that will predict the likelihood 
of a person developing pancreatic cancer at an early stage using various mentioned 
factors which may impact the development of pancreatic tumor to ensure timely 
treatment. 
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BACKGROUND 
 
Limitations of the existing methods in detecting pancreatic cancer at an early stage 
exist because of lack of symptoms. Pain in abdomen, jaundice, loss of weight are 
common early symptoms of pancreatic cancer. Some of the other symptoms are back 
pain, anorexia, heartburn, and dysgeusia (Risch, Yu, Lu, & Kidd, 2005). It is often 
the case that symptoms of pancreatic cancer can be confused at later stages with 
other ailments. Medical imaging is used to detect the presence of pancreatic cancer 
which results in discovery of masses. The noticeable masses are generally detected 
at a later stage. At this point, the survival rate of pancreatic cancer drastically 
decreases. Thus, lack of imaging technology to detect pancreatic cancer at a 
premalignant stage calls for the need to find newer methods which may aid in earlier 
detection of this disease. (See Appendix B for imaging technology details) 
 
Use of Biomarkers in Detection 
Presence of biomarkers is one of the important techniques in early detection of 
pancreatic cancer. Biomarkers are characterized by high presence of cellular 
molecules such as proteins, antigens, etc. in pancreatic cancer patients. They can be 
found using tissue biopsy of liquid biopsy (Qi, et al., 2018). Samples collected for 
studying biomarkers before the diagnosis are very less, but they are the ones which 
are preferred over the samples of patients already diagnosed with pancreatic cancer 
(O'Brien, et al., 2015). 
Carbohydrate antigen 19-9 (CA19-9) is one of the most common biomarkers used 
presently, with a sensitivity between 69% - 98% and a specificity between 46% - 
98%. O’Brien et al. observed that there was a detectable surge in CA19-9 levels 3 
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years prior to PDAC diagnosis (O'Brien, et al., 2015). However, CA19-9 is not 
specifically related to pancreatic cancer as it is also detected in gastrointestinal 
tumors and hence cannot be sufficient enough to be considered alone as a biomarker 
in identification of pancreatic cancer. 
 
Existing Research in Genomic Biomarkers 
There has been a significant body of research in detection of pancreatic cancer-
causing cell mutations. Various literature sources study the presence of specific 
biomarkers which may lead to pancreatic cancer and there is a considerable 
development in this research suggesting the presence of certain genetic material or 
biomarkers in the tissue specimen of patients is indicative of presence of malignant 
tumors in their pancreas. Experiments help to identify characteristics of these 
biomarkers and how they can potentially cause PDAC. Traditional biomarker 
detection techniques use tissue biopsy method to detect the presence of malignant 
tumors. This involves sectioning the patient’s tissue using surgical or needle biopsy 
(Qi, et al., 2018). In contrast to the invasive traditional biopsy techniques, Z. Qi et 
al. suggest that inference based on presence of a single biomarker, or study of a 
single biopsy sample may provide only limited information as the tumors and their 
genetic composition is found to be heterogenic. They argue that due to the limited 
true positive and true negative rates provided by biomarkers such as 
carcinoembryonic antigen (CEA) and carbohydrate antigen, there is a need for a 
better technique that can monitor new biomarkers. This study further suggests that 
liquid biopsy is a promising technique because of its non-invasiveness and 
effectiveness in detecting circulating tumor cells (CTCs) and cell-free circulating 
nucleic acids (cfNAs) which keep circulating in the body fluids such as blood. 
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However, one of the major limitations associated with liquid biopsy technique is that 
it relies more on body fluids rather than cancerous tumors to detect the biomarkers, 
which may produce misleading conclusions (Qi, et al., 2018).  
A. Gharibi et al. study the presence of other biomarkers which may indicate the 
presence of ductal tumors. They analyzed and found that integrin alpha 1 (ITGA1), 
acts as an ideal biomarker for diagnosis and therapeutic technique for PDAC. 
Presence of ITGA 1 is detected in high quantity in 42% of the tumor tissue of PDAC 
patients, whereas it does not occur in the normal pancreatic ductal epithelial cells 
(Gharibi, et al., 2017). Thus, it can be used effectively in the PDAC detection. 
In another study, A. Gharibi, Y. Adamian, and J.A. Kelber examine various genetic 
mutations and suggest that Kirsten rat sarcoma (KRas) is the most frequently 
observed gene that is mutated in PDAC related cases (Gharibi, Adamian, & Kelber, 
2016). It is followed by other genes including p53, p16, SMAD4, PUC1, and SRC. 
These genetic materials after undergoing mutations, lead to inappropriate 
proliferation of cells in pancreas. Amongst these, p53, p16, and SMAD4 are tumor 
suppressing transcription factors, which normally arrest the progression of cell 
cycle; however, their mutated presence in abnormal quantities or their absence, leads 
to cell proliferation (Gharibi, Adamian, & Kelber, 2016). Hence, these are some of 
the important biomarkers in PDAC treatment.  
Similarly, J. A. Kelber et al. found that Pseudopodium-Enriched Atypical Kinase 
One (PEAK1) helps in regulation of cell migration and proliferation. It is a 
biomarker with therapeutic target in PDAC, which regulates the necessary cell 
migration characteristics such as shape change of cells (Kelber, et al., 2012). Thus, 
this research paper concludes that PEAK1 plays a major role in limiting cancer cell 
migration as well as growth.  
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However, one major limitation of these studies is that they consider only a few 
genetic material or biomarkers which might prove unreliable given that the tumors 
may contain a variety of genetic mutations, but the biomarkers under consideration 
are limited. Moreover, it is observed that barring some genes, not all the biomarkers 
can aid in detecting of pancreatic cancer early. 
 
Circulating Tumor Cells  
Circulating Tumor Cells (CTCs) are the tumor shed cells which circulate in the blood 
stream of the cancer patients. A study found out that out of 12 pancreatic cancer 
subjects under consideration, 11 had KRAS gene mutations in their CTCs (Court, et 
al., 2016). Court et al. concluded that at least 10 CTCs should be present in order to 
detect KRAS mutations. Moreover, 7.5 mL of blood sample contains only about 1-
50 CTCs along with more than a million white blood cells. Hence to detect CTCs in 
blood sample, a test with a high sensitivity and specificity is needed because of lesser 
number of CTCs in bloodstream (Court, et al., 2016). CTCs are believed to be a good 
prognostic biomarker, but out of all the CTCs detaching from tumors, only 0.01% 
develop into metastases. Newer techniques are being formulated to detect CTCs as 
they are great potential biomarkers in cancer development. 
 
Sequencing 
Classification of gene mutations is achieved using various sequencing technologies. 
Study by Lawrence, et al., mentions methods such as Mutation Significance of 
Covariance (MutSigCV) which are widely used to classify gene mutations from the 
tumor tissue of an affected individual. Lawrence et al. used MutSigCV to discover 
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abnormal variation in mutation frequency and spectrum observed in tumors for 
different cancer types by applying the technique on exome sequences from 3,083 
tumor–normal pairs. Cancer related genes or mutations truly found in cancerous 
tumors are found out by MutSigCV by introducing the analysis with mutational 
heterogeneity. (Lawrence, et al., 2013). Using this sequencing approach, genes such 
as KRas, TP53, CDKN2A, Smad4, BCLAF1, IRF6, FLG, AXIN1, GLI3 and 
PIK3CA were found to be mutated expressively. Pancreatic tumor cells were 
separated by microdissection approach from the microenvironment in 109 affected 
patients using surgical resection.  Various other sequencing techniques also aided in 
discovering novel mutations in these tumorous cells which underwent whole-exome 
sequencing technique (Witkiewicz, et al., 2015) (See Appendix C for more details 
on sequencing details).  
 
Machine Learning 
Machine learning has proved to be a promising technique to detect pancreatic 
cancer-causing genetic mutations. In an interesting study, G. P. Way et al. developed 
a machine learning model to detect abnormal Ras activation in the cancer tumors 
using the knowledge of Kirsten Rat Sarcoma (KRAS), Neuroblastoma Rat Sarcoma 
(NRAS) and KRAS, also known as transforming protein p21. The mutations in Ras 
pathway genes are known to drive PDAC. A classification model was developed for 
distinguishing the aberrant Ras pathway activity in tumors using features such as 
RNA-seq, copy number, and mutation data. A logistic regression classifier is used 
to train a model by combining these features from 33 types of cancers from The 
Cancer Genome Atlas (TCGA) PanCanAtlas database. The model learned a 
combination of weights and gene related important scores that separate aberrant 
patterns (Way G. P., et al., 2018). The results of this classification model by the 
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authors were observed in terms of area above 84% covered by the receiver operating 
characteristic (AUROC) curve and above 63% covered by the precision recall 
(AUPR) curve (Way G. P., et al., 2018).  
In other research, J. Jeon et al., considered mutated genetic data as the dataset from 
the Catalogue of Somatic Mutations in Cancer (COSMIC) database. In general 
terms, they computed the probability of 15,663 proteins of being an appropriate drug 
target in case of treatment of cancers such as pancreatic cancer, breast cancer, and 
ovarian cancer. Using features such as mRNA expression intensity score, gene 
essentiality score, DNA copy number and mutation occurrence, 3 classifiers were 
developed with the help of support vector machine (SVM) and RBF kernel. SVM 
perform exceptionally well in inferring gene-disease correlation and in identifying 
the drugs with the target disease (Jeon, et al., 2014). It was further found that of the 
three diseases they considered the SVM could predict 43 of the 69 drug targets 
considered. Out of all the three classifiers, the combined accuracy obtained was 
91.69%, meanwhile the specificity was 91.91%. A major drawback of this study is 
that these features provide little throughput screening and relatively low coverage of 
human genomic data which confines their use in generalized identification of 
genome-wide drug targets (Jeon, et al., 2014) 
Thus, using machine learning in pancreatic cancer detection is a novel technique that 
can aid in early diagnosis of the disease. It can also create a breakthrough in the early 
treatment of this disease which is the goal. But it still has a scope for improvement 
as currently, only limited genomic data has been considered presently. 
Existing Research in Evidence Based Approach  
The work done by Sharghi which has been extended in this study is based on a 
similar evidential reasoning approach (Sharghi, 2019). This dataset gathered for this 
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study consisted of mutations from the Cancer Genome Atlas – Pancreatic 
Adenocarcinoma (TCGA-PAAD) project. Sharghi used these mutations to find the 
cases from other cancer projects that shared the mutations from TCGA-PAAD 
project (Sharghi, 2019). A permutation factor was made use of, to find the mutation 
entries for every individual case. This dataset had an imbalance of classification 
labels as only a certain percent of data was queried for each case.  The Support 
Vector Classifier was trained on the dataset of unique gene mutation permutation 
and its pancreatic cancer label. An average precision score of 92% was obtained 
along with a ROC AUC of 92%. As per Sharghi, even though the results of the 
classifier were promising, its performance was still questionable owing to the limited 
size of 185 cases. Sharghi expressed a need for utilizing a larger dataset to find more 
common gene mutation combinations (Sharghi, 2019). The present study tries to 
overcome this limitation by considering a larger volume of dataset with mutations 
observed in every project in the GDC portal along with additional features such as 
impact of the variant on protein and the project in which the mutation occurred. 
Further, various experiments were carried out considering different scenarios 
regarding the smoking and drinking history of individual, family and personal 
history along with the machine learning prediction, biopsy site, and even the 
sequencing reads and NGS technologies. These scenarios were input to an evidential 
reasoning model which produced promising results.  
 
 Addressing the Technological Gaps 
The present diagnostic methods fail to detect pancreatic cancer in the early stage 
resulting in lowering the rate of survival of this disease. According to Gharibi et al., 
pancreatic cancer starts metastasis 10 years prior to showing symptoms in the body 
of the patient (Gharibi, et al., 2017). Thus, if the mutations in the genes leading to 
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pancreatic cancer are detected early, the cancer can be removed effectively before it 
spreads beyond the pancreas, after which it becomes very difficult to treat the 
disease.  
Further, diagnosing a lethal disease like pancreatic cancer using a few biomarkers or 
analyzing limited genomic data using machine learning may prove unreliable and 
inaccurate. The reason behind this being that there are many factors responsible for 
causing the aberrant mutation of cells in the pancreatic tissues. These factors may be 
environmental (tobacco intake, alcohol consumption, etc.) or even hereditary 
(genetic mutations occurring due to inherited conditions) (See Appendix A for more 
details regarding the causes of pancreatic cancer). All these factors including the 
statistical data could be vague, inaccurate, diverse, imprecise, or even insufficient to 
certain extent.  Moreover, if age and ethnicity wise data of people at higher risk is 
considered, there is a chance that only a subset of a wider population being diagnosed 
eventually  (Sharghi, 2019). 
The Belief Function (BF) and evidential reason calculi is a part of a sophisticated 
mathematical approach used to formulate reasonable and precise results regarding 
likelihood of developing pancreatic cancer. It does this in a more flexible and less 
restrictive manner than the traditional statistical and probabilistic approaches 
(Lowrance, et al., 1991).  
A useful knowledge source can be developed using imperfect and diverse 
information such as the genomic structure, alcohol consumption habits, smoking 
habits, health history, biopsy location, etc. This tactic can aid in early cancer 
diagnosis if supplied with real time data, by using belief functions and evidence-
based reasoning approach. The work described in this report attempts analyzing the 
feasibility of an evidence-based approach to represent reasonable information from 
complex and miscellaneous dataset. 
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APPROACH AND METHOD 
Even though machine learning approach is establishing a hold in the diagnosis 
world, presently, there are no techniques that could consider a plethora of significant 
factors such as medical and personal history, smoking or drinking history by 
screening the patient and estimate the likelihood of developing the pancreatic cancer 
before its metastasis (Sharghi, 2019). Data analysis techniques depend on limited 
genomic data supplied to machine learning classifiers predicting an outcome. This 
can be exemplified in the study by Way et al. where a machine learning classifier 
detected altered Ras activity with promising results, but the data considered was 
limited to genomic evidence and transcriptome (Way G. P., et al., 2018). To 
overcome these shortcomings, a sophisticated and powerful mathematical calculus 
is needed to represent, combine, and draw inferences from such types of data and 
information. With the aid of available genetic material such as the mutations 
undergone by the genes, and other factors affecting the likelihood of developing 
pancreatic cancer, a screening option could be developed to detect whether an 
individual stands a greater risk of suffering from this cancer. 
Multiple environmental and hereditary factors affect the pancreatic cancer detection. 
Evidential Reasoning (ER) approach draws information from these diverse factors 
and helps combine it to produce the likelihood of developing pancreatic cancer. 
Machine learning model is one of the diverse yet useful sources which analyzes 
genetic data to predict if a subject has developed pancreatic cancer or not. The 
machine learning (ML) classifier is based purely on analysis of genomic data, it lacks 
considering the impact of other factors responsible for genetic alterations such as the 
medical history or smoking and alcohol habits. Evidential reasoning allows us to 
incorporate all these factors along with the ML prediction, without knowing its 
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distribution even though some of the data may be imprecise, estimated, and 
incomplete. ML prediction is also affected by factors such as the quality of 
sequencing reads and the type of technology used to sequence the genomic data. 
Moreover, ML prediction is impacted by the amount of genetic material considered 
during the biopsy and its site and structure. Even though the ML classifier does not 
use these factors as its features, the ER model allows to amalgamate ML prediction 
results along with all of these factors and forms a consensus on the prediction of 
developing pancreatic cancer. 
Heavy tobacco use constitutes around one fourth of cancer related deaths with a 5-6 
fold increased risk of developing pancreatic cancer due to smoking a pack of 
cigarettes in a day (Pandol, Apte, Wilson, Gukovskaya, & Edderkaoui, 2012), and 
an elevated risk of about 1.5 to 6-fold due to drinking alcohol (Gupta, Wang, Holly, 
& Bracci, 2010). Thus, evidences of smoking and drinking histories are features that 
can be helpful in balancing the results of an otherwise unbiassed machine learning 
classifier, towards a higher belief of having pancreatic cancer (Sharghi, 2019). 
Moreover, DNA Single Nucleotide Polymorphisms (SNP) comprising of 
homopolymer region may lead to sequencing errors negatively affecting the 
accuracy of machine learning classifier using the genomic data. Thus, errors 
occurring while sequencing genomic data can be considered as another factor for 
orienting the machine learning results (Sharghi, 2019). In this way, the evidential 
reasoning approach can be used to make a more precise prediction about the 
pancreatic cancer diagnosis using mathematical calculus by looking past the 
traditional statistical and probabilistic approach (Sharghi, 2019).Thus, rather than 
relying on a single source of data,  this approach takes into account various factors 
which may be diverse and imprecise. Each of these factors are assigned a belief and 
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are weighed together to make a final decision which measures the support in favor 
of pancreatic cancer prediction as well as no pancreatic cancer prediction.  
The approach used in evidential reasoning model considers as input, factors such as 
results of a machine learning classifier, patient’s medical history, family history, 
drinking and smoking history, the type of NGS technology used to obtain patient’s 
genomic data, biopsy site and cell structure, sequencing read, and amount of genetic 
material. Every input factor is known as a frame and a collection of such frames is 
called a gallery. 
Every frame comprises of propositions defining all the possible scenarios. No two 
scenarios can be true together at the same time. A probability signifying truth of the 
statement is assigned to each of these propositions. A discount value applied to these 
frames indicates the reduction of belief impact in that frame. Such a grid of 
interconnected propositions ultimately produces a single resulting prediction of 
likelihood of pancreatic cancer as shown in the Figure 1. Propositions for a given 
frame can either be discrete or continuous in nature. For instance, the frame 
‘Drinking History’ may have propositions such as ‘low’, ‘medium’, or ‘high’, 
whereas the frame ‘ML Prediction’ may have propositions such as ‘PC’ (pancreatic 
cancer) or ‘NOT_PC’ (no pancreatic cancer). All the features (sequencing read, 
family medical history, smoking history, etc.) are represented as similar frames and 
are input to the evidential reasoning model. A compatibility relation is the subset of 
cross product between two frames meaning that it is the joint possibility distribution 
of the frames under consideration. The generalization of the compatibility relation 
is defined as ‘the multiplication of possibility distributions’ (Yager, Liu, Dempster, 
& Shafter, 2008). It is defined for every frame in the evidential model. A new body 
of evidence forms as a result of merging of frames into one another as per 
Dempster’s Rule of Combination evidence (Yager, Liu, Dempster, & Shafter, 2008). 
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The propositions in this project are synthesized using NIH GDC dataset (see 
Appendix F for more evidential reasoning details). 
 
Figure 1. Evidential Reasoning Model 
A machine learning model was developed to determine the classification whether a 
subject has or does not have pancreatic cancer. The results of the classification 
obtained from the developed machine learning model is one of the frames which are 
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provided to the evidential reasoning model. (For more information on how the 
classifier was built, please refer Appendix E)  
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EXPERIMENTAL METHOD 
This study in this project uses the following hypotheses: 
Ho: Will not be able to detect pancreatic cancer significantly earlier than currently possible 
HA: Will be able to detect pancreatic cancer significantly earlier than currently possible 
 
In order to detect the cancer at an early stage, it is necessary to examine the type of 
mutations undergone by genetic data which may help in predicting the potential of 
developing the pancreatic cancer. A vast amount of genetic data from cases related 
to different kinds of cancer can be analyzed to infer the type of mutations the genes 
undergo that lead to pancreatic cancer. For this purpose, data from the National 
Cancer Institute (NIH) Genomic Data Commons (GDC) is taken into consideration. 
The NIH GDC portal contains information related to 22,872 genes in total, with 64 
different projects which are different types of cancer. There are 3,142,246 total 
number of mutations associated with these genes and projects in the NIH GDC data. 
The experiment consists of data specific to all the cancer related projects. The GDC 
portal also associates the impacts with every genetic mutation. One of the important 
features of this experiment is the consideration of the impact caused by the genetic 
mutation (For more details related to the ‘impact’ field, see Appendix D). The 
machine learning classifier trained on the dataset considers the impact associated 
with every mutation record. To sum up the working of the machine learning 
classifier, features such as genes, and mutations along with their lethality and the 
disease associated it were considered to classification model predicting whether a 
subject suffers from pancreatic cancer or not. Since the features used are dependent 
variables that cannot be considered as separate features, they were combined into a 
single string feature. This was a binary classification model built using support 
vector machine classifier. The kernel ‘Radial Basis Function’ (RBF) was used as it 
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gives better cross validation results than linear or polynomial kernels. A cross 
validation with 10 splits and 3 repeats was applied on the training dataset. (Refer 
Appendix E to understand more details on how the machine learning model was 
built). This model produced ~85% average accuracy with a mean Receival Operator 
Characteristic – Area Under Curve (ROC) of ~0.834. It showed a 
decent class separability with a fairly good accuracy. 
The method for evidential reasoning model was followed as discussed in this section.  
The evidential reasoning model will predict the belief of developing pancreatic 
cancer as well as not developing it based on the combination of propositions and 
their respective masses provided as input. the ‘mass’ of a specific proposition is a 
basic probability number assigned to it (Yager, Liu, Dempster, & Shafter, 2008). It 
can be interpreted as the amount of belief that one has in the proposition. (See 
Appendix F to learn more about the evidential model engineering). As the 
propositions and their masses change, so will the prediction results. While some 
combinations like high smoking history with a personal history of cancer will lead 
to increase the likelihood of diagnosing pancreatic cancer, other combinations like 
biopsy site away from pancreatic region with regular cell shape along with  machine 
learning prediction of not developing pancreatic cancer is expected to produce a 
lower likelihood of pancreatic cancer development. Thus, the model will be tested 
based on the computed belief value in support of pancreatic cancer for the given 
scenario. 
The baseline input and discount rates displayed in Table I and Table II are used to 
initialize the evidential reasoning experiments. Each of the frame is assigned a 
certain discount value indicating a relative importance of input features and/or 
reliability of the source of the information. Initial values were selected based on a 
subjective estimate of relative importance and credibility.  
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Table I 
Baseline Propositions and Corresponding Support 
 
 
Table II 
Discount Rates and Corresponding Frames 
 
The grouping of the baseline discount rate and initial inputs gives the following 
baseline output: 
Belief Of Having Pancreatic Cancer Lies Between:      (0.064, 0.142) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.857, 0.935) (0)|--------**|(1) 
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Certain experiments are conducted by modifying the baseline propositions and the 
support in them. Opinions are translated via compatibility relations and a consensus 
is formed using Dempster’s rule. Dempster’s rule can be repeatedly applied to the 
previous combination and combined further with an additional mass distribution if 
there is any, thus forming a new consensus (Wesley & Graham, Evidence-Based 
Decision Support For The Biopharmaceutical Industry, 2006). Ultimately, an 
evidential interval (EI) within the belief function calculus depicting the likelihood 
of developing pancreatic cancer is computed for each scenario. This is done by 
conveying, translating, and combining the opinions as mentioned before. Lower 
(Spt) and upper (Pls) bounds of an EI describe the degree of support attributed to the 
given proposition because of the current opinions (Wesley & Graham, Evidence-
Based Decision Support For The Biopharmaceutical Industry, 2006). Note that [Spt, 
Pls] ⊆ [0,1]. The evidential reasoning model is tested using the following 
combination of random variables to understand how each of the experiment affects 
the likelihood of developing pancreatic cancer: 
 Machine learning prediction, smoking history, family health history 
 Machine learning prediction, and drinking history 
 Machine learning prediction, biopsy location, and amount of genetic material 
 Machine learning prediction, sequencing technology utilized, and quality of 
sequencing read 
In the experiment with combination of Machine learning prediction, smoking 
history, and family health history we change the propositions and masses assigned 
to these three frames and check how the increased belief in an individual with high 
smoking history and a family health history of having cancer increases support in 
the ML prediction of pancreatic cancer and increases the evidential interval of belief 
in an individual having pancreatic cancer. In other experiment, we combine the ML 
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prediction, drinking history, and personal health history frames to determine how 
the drinking history and personal health history are correlated to the ML prediction 
and how their proposition values and masses assigned to them affect the evidential 
interval. Further, we check how the biopsy location, and cell structure along with the 
quantity of genetic material affects the evidential interval and how they support the 
ML prediction as their values and masses change. Lastly, the impact on ML 
prediction with changes in NGS technology and quality of sequencing reads are 
tested. By changing their propositions and masses, we combine these two frames to 
evaluate that the ML prediction becomes less reliable, resulting in a lower evidential 
interval for pancreatic cancer as the sequencing reads become more error prone by 
having a high guanine cytosine (GC) content and high homopolymer regions. 
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EVALUATION OF RESULTS  
 
The results are evaluated by training an SVC classifier and assessing its 
performance. A cross validation of 10-folds repeated 3 times was applied to the SVC 
classifier to measure the variance. An accuracy of 84.70% was achieved. The model 
was stable with a low standard deviation of +/- 1.297%. The mean ROC AUC of 
0.834, while an average precision-recall score for this classifier was 0.67. Figure 2 
and Figure 3 show the area covered by the receiver operating characteristic curve 
(AUC-ROC) and area covered by the precision-recall (AUC-PR) curve of the model.  
 
Figure 2.  Support Vector Classifier ROC 
 
While Figure 2 shows an AUC-ROC of 0.834 suggesting that the model has a good 
measure of separability as it is nearer to 1. Precision-Recall Curves are an intuitive 
measure when evaluating imbalanced dataset like the one for this study. In Figure 3, 
there is a consistent rise in precision as the recall increases. But a sharp drop in 
precision at around 0.8 recall indicates that there are large numbers of fall positives 
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at that point. This means that the predicted labels are incorrect when compared to 
the training labels. In the imbalanced dataset, since the minority class is the positive 
class, there could be a lot of negative examples that could become false positives. 
Conversely, a fewer positive examples could become false negatives, hence the steep 
drop in the precision. 
 
Figure 3. Support Vector Classifier Precision-Recall 
Figure 4 and Figure 5 demonstrate the confusion matrix obtained without and with 
normalization. Higher proportion of true positives and true negatives suggest that 
the model performs a good classification of the test data. Although the results 
obtained for the machine learning classifier are promising, they still can be improved 
further if the GDC data contains more pancreatic cancer related records. For the 
model to avoid overfitting, there is a need to remove the imbalance present in the 
data. Efforts to do this were made, but the non-pancreatic cancer records will remain 
more compared to the pancreatic cancer project records which is quite obvious.  
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Figure 4. Confusion matrix, without normalization 
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Figure 5. Confusion matrix, with normalization 
ER Experiment 1 
 
This experiment focuses on the effect of ML prediction frame on the evidential 
reasoning model. 
 Baseline input 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.063, 0.147) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.853, 0.936) (0)|--------**|(1) 
 
 The baseline input of ML prediction is changed from NOT_PC to PC with the 
same mass 0.5 to see how it affects the evidential interval.  
 
Belief Of Having Pancreatic Cancer Lies Between:  (0.26, 0.374) (0)|--**------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.626, 0.739) (0)|------**--|(1) 
 
The results show what after changing from NOT_PC to PC, there is an increase 
in the evidential interval but since the mass assigned is only 0.5, it is a small 
increase. 
 
 Suppose we do not have any information about other frames but just the results 
of the ML prediction. In this scenario, the mass of the ML prediction frame is set 
to be 0.85 (accuracy of ML classifier) with the proposition PC without changing 
the baseline beliefs in other propositions to see the effect on evidential intervals.  
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.507, 0.585) (0)|-----*----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.415, 0.492) (0)|----*-----|(1) 
 
Now the evidential interval of having pancreatic cancer further increases, while 
the evidential interval of not having pancreatic cancer decreases as expected. 
  
Thus, it is observed that if the belief in the ML prediction is changed  from NOT_PC 
to PC, while keeping the rest of inputs constant, the evidential interval of pancreatic 
cancer increases and the interval for not pancreatic cancer decreases to a certain 
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extent eventually both attaining almost similar values when we are considerably 
confident about the ML prediction with mass 0.85. 
 
ER Experiment 2 
 
This experiment evaluates the effect of smoking history along with family medical 
history on the likelihood of developing pancreatic cancer. Assuming that a person 
does not have an active smoking history and moreover there is no family history of 
cancer, it is highly unlikely that the person would develop pancreatic cancer. On the 
other hand, if the smoking history is high with previous family history of cancer, the 
evidential reasoning model is expected to predict more likelihood of developing 
pancreatic cancer. 
 Baseline input 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.063, 0.147) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.853, 0.936) (0)|--------**|(1) 
 
 ML Prediction is set to PC with mass 0.85, smoking history set to HIGH with 
mass 0.9 along with family history set to CANCER with mass 0.8 to check if the 
high smoking and family history of cancer causes supports the ML prediction of 
having pancreatic cancer. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.956, 0.974) (0)|---------*|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.026, 0.043) (0)|*---------|(1) 
 
The evidential interval rises significantly showing that the smoking history and 
family history does support the ML prediction of having pancreatic cancer as was 
expected. 
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 Family history is set to NO_CANCER with a mass 0.9 but Smoking History is 
still HIGH with mass 0.9 to check how the prediction is affected for such 
scenario. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.686, 0.721) (0)|------**--|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.279, 0.313) (0)|--**------|(1) 
 
Such a combination reduces the evidential interval of having pancreatic cancer 
as was expected because there is no family history of cancer. 
 
 Smoking History set to MEDIUM with a mass of 0.9 and Family Medical History 
set to CANCER with a mass 0.5 and ML prediction of NOT_PC with mass 0.5 
to observe how setting affects prediction interval. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.302, 0.454) (0)|---**-----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.545, 0.697) (0)|-----**---|(1) 
 
The evidential interval of pancreatic cancer reduces because the ML prediction 
is set to NOT_PC and even the smoking history is medium but only the family 
has a medical history.  
 
 ML Prediction changed to PC with mass 0.85, Smoking History set to LOW with 
a mass of 0.9 and Family Medical History set to NO_CANCER with a mass 0.9 
to check if the interval for PC prediction reduces. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.214, 0.248) (0)|--*-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.752, 0.785) (0)|-------*--|(1) 
 
The interval for PC prediction reduces as expected. 
 
From the above experiments, it is observed that as the smoking history changes from 
LOW to HIGH, Family Medical History from NO_CANCER to CANCER, the 
evidential interval increases rapidly. It is seen that the ML Prediction results of PC 
further support increasing the interval. As the variations are made in the propositions 
in Smoking History and Family Medical History, there are changes in the interval 
depending also on the ML prediction mass.  With HIGH Smoking History with mass 
0.9 but Family History of NO CANCER with mass 0.9 the evidential interval 
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becomes (0.686, 0.721) as the ML Prediction is still set to PC with mass 0.85.  If the 
Smoking History is reduced to MEDIUM with mass 0.9 but with Family History of 
CANCER and ML prediction of NOT_PC, the interval reduces to (0.302, 0.454).   
Eventually, with LOW Smoking History with mass 0.9 and NO CANCER Family 
History of 0.9 along with ML prediction set to PC with mass 0.85, the interval further 
reduces to (0.214, 0.248) suggesting that the propositions and their masses affect the 
prediction of evidential reasoning model as expected and the ML prediction is 
playing a supportive role in this. 
 
ER Experiment 3 
This experiment will try to analyze how the personal medical history, drinking 
history and the ML prediction correlate with each other. If a person does not have 
any history of cancer and has a low drinking history, the chances that he will develop 
pancreatic cancer are low. But with the ML prediction of pancreatic cancer and a 
medium to high drinking history and personal history of cancer, the expected 
evidential interval of developing cancer is high.  
 Baseline input 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.063, 0.147) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.853, 0.936) (0)|--------**|(1) 
 
 ML Prediction is set to PC with mass 0.85, to see if there is a change in the 
prediction given that the drinking history set to HIGH with mass 0.8 and 
Patient_Med_History set to CANCER with mass 0.9  
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.795, 0.845) (0)|-------**-|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.155, 0.204) (0)|-**-------|(1) 
 
 The evidential increases as per expectations and thus the high medical history 
and drinking history support the PC prediction. 
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 Drinking history set to MEDIUM with mass 0.3 and Patient_Med_History set to 
CANCER with mass 0.7 given the ML prediction of PC to see how this affects 
the evidential interval. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.612, 0.705) (0)|------**--|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.295, 0.387) (0)|--**------|(1) 
 
The evidential reasoning interval reduces a little as only drinking history was 
changed which was expected.  
 
 Drinking history set to HIGH with mass 0.9 and Patient_Med_History set to 
NO_CANCER with mass 0.9 and PC prediction to NO_CANCER with mass 0.8 
to see if the prediction is impacted. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.202, 0.258) (0)|--*-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.742, 0.797) (0)|-------*--|(1) 
 
The evidential interval for pancreatic cancer reduces as per expectations. 
 
 ML Prediction is set to NOT_PC with mass 0.8, to see if the interval for 
prediction decreases given the drinking history is set to LOW with mass 0.2 and 
Patient_Med_History set to NO_CANCER with mass 0.9 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.02, 0.05) (0)|*---------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.95, 0.979) (0)|---------*|(1) 
 
This causes the pancreatic cancer evidential interval to reduce sharply as was 
expected. 
 
Here, different scenarios are created to evaluate the effect of drinking history and 
personal medical history on the evidential intervals. With ML prediction as PC with 
a mass 0.85 and Drinking History set to HIGH with mass 0.8 and Personal Medical 
History set to CANCER with mass of 0.9, there is an upsurge in the evidential 
interval of belief in developing pancreatic cancer from  (0.063, 0.147) to (0.795, 
0.845). With MEDIUM Drinking History with a mass of 0.3 the interval decreases 
by a small amount to (0.612, 0.705). Finally, as the Drinking History is set to LOW 
with mass 0.2 and the Medical History to NO_CANCER and ML Prediction to 
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NO_PC both with masses 0.8, there is a decline in the evidential belief interval to 
(0.02, 0.05), thus suggesting that the model behaves as was expected. 
 
ER Experiment 4 
In this experiment the impact of biopsy site and amount of genetic material is 
observed on the ML prediction and how it affects the evidential reasoning model 
prediction.  It is expected that if the biopsy location is near pancreas with irregularity 
in the cell result, then there might be a possibility of greater risk of cancer than if the 
biopsy location is far off pancreas with regular cell result and low amount of genetic 
material. With lesser amount of genetic material, it might be not enough DNA 
material available to make a sensible machine learning prediction as opposed to 
when the genetic material is more. For a greater likelihood of developing pancreatic 
cancer, it is expected that the amount of available genetic material is high and the 
cells nearing the pancreatic region are irregular.  
 Baseline input 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.063, 0.147) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.853, 0.936) (0)|--------**|(1) 
 
 Change amount of genetic material to LARGE with a mass of 0.6 and change 
biopsy site and cell result to NEAR PANCREAS and REGULAR with a mass of 
0.8 and ML Prediction to PC with a mass of 0.5 to see how it affects the PC 
interval. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.174, 0.251) (0)|-**-------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.749, 0.825) (0)|-------**-|(1) 
 
The evidential interval for PC decreased as per the expectations as the amount of 
genetic material is large along with biopsy site near pancreas with regular the cell 
structure. 
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 The proposition amount of genetic material is changed from LARGE to 
MEDIUM with a mass of 0.7 and change biopsy site with cell result to NOT 
NEAR PANCREAS and IRREGULAR with mass of 0.9 to see if the PC 
prediction is changed given ML Prediction is set to PC with a mass of 0.5 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.37, 0.531) (0)|---***----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.469, 0.63) (0)|----***---|(1) 
 
The PC interval increases moderately between 0.37 and 0.53 as was expected 
given the modified propositions. 
 
  
 Amount of genetic material is set to SMALL with a mass of 0.8 and biopsy site 
and cell result set to NEAR PANCREAS and IRREGULAR given a mass of 0.9 
and ML Prediction to PC with a mass of 0.85 to see if the evidential interval for 
having PC supports the input by increasing 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.838, 0.88) (0)|--------*-|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.119, 0.162) (0)|-*--------|(1) 
 
The evidential interval for PC prediction surges as expected. 
 
Observation of this experiment suggest that the ML prediction of PC are not strongly 
supported by a LARGE amount of genetic material as well as the results of biopsy 
NEAR pancreas with REGULAR cell results. Further, with a MEDIUM quantity of 
genetic material with mass 0.5 along a mass of 0.9 assigned to the biopsy site and 
cell result of NOT NEAR PANCREAS and IRREGULAR and PC prediction of 
mass 0.5 increases the pancreatic cancer evidential interval from (0.174, 0.251) to 
(0.37, 0.531). This interval further increases as experiments are performed with 
different combinations changing the propositions eventually to soar to an interval of 
(0.838, 0.88) when the amount of genetic material is changed to SMALL with a mass 
of 0.8, biopsy site and cell result to NEAR PANCREAS and IRREGULAR with a 
mass of 0.9 and ML Prediction to PC with a mass of 0.85. 
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ER Experiment 5 
Lastly, this experiment tries to observe the impact of sequence reads quality along 
with the NGS technology used on the ML model. The anticipated scenario is that the 
ML should become less dependable as the sequencing reads become more erroneous 
meaning that they produce high guanine cytosine (GC) content and high 
homopolymer regions.  
 Baseline input 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.063, 0.147) (0)|**--------|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.853, 0.936) (0)|--------**|(1) 
  
 The proposition for sequencing reads is set to HIGH GC HIGH HMR with a mass 
of 0.9 to check to see if there is a change in prediction given the ML prediction 
of PC with mass 0.85. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.332, 0.435) (0)|---**-----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.565, 0.667) (0)|-----**---|(1) 
 
It is seen that the evidential interval obtained for pancreatic cancer is moderately 
low suggesting error prone sequencing reads make the ML prediction unreliable 
and produce lower interval which is expected. 
 
 The mass assigned to the proposition for NGS tech is set to 0.9 to see if there is 
a change in prediction given a high GC count and high homomeric region. 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.332, 0.436) (0)|---**-----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.564, 0.667) (0)|-----**---|(1) 
 
There is no change in the evidence interval showing lack of impact of the NGS 
tech frame. 
 
 
 The proposition for NGS tech is changed from ionTorrent to ILLUMINA to 
check if there is a change in the prediction given a high GC and high homomeric 
region. 
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Belief Of Having Pancreatic Cancer Lies Between:      (0.332, 0.436) (0)|---**-----|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.564, 0.667) (0)|-----**---|(1) 
No change is observed in the evidential interval by changing the type of NGS 
technology. 
 
 The proposition NGS tech is changed back to ionTorrent and sequencing read is 
set to MOD GC LOW HMR with mass 0.9 given an ML prediction of PC with 
mass 0.85 to see if the interval changes 
 
Belief Of Having Pancreatic Cancer Lies Between:      (0.768, 0.804) (0)|-------**-|(1) 
Belief Of Not Having Pancreatic Cancer Lies Between:  (0.195, 0.231) (0)|-**-------|(1) 
 
The evidential interval for PC increases considerably from (0.332, 0.436) to 
(0.768, 0.804) as expected because lower quantity of GC and homomer regions 
produce less faulty sequencing readings thus making the ML prediction more 
reliable. 
 
Changing the ML prediction from NO_PC to PC with a mass 0.85 increases the 
evidential interval from (0.063, 0.147) to (0.507, 0.585). Further, as the sequencing 
read frame is changed from LOW GC LOW HMR to HIGH GC HIGH HMR, the 
evidential interval of belief in developing pancreatic cancer decreases to (0.332, 
0.435). The model behaves as expected, meaning that that this change in the 
sequencing model leads to the possibility of the sequencing read may lead to errors, 
effectively making the ML prediction less reliable. Another observation is that 
changing the NGS tech mass or its value from ION TORRENT to ILLUMINA 
hardly affects the evidential interval. Even changing the sequencing read to LOW 
GC HIGH HMR does not affect the interval. However, an upsurge in the evidential 
interval of belief of having pancreatic cancer is observed as the NGS tech value is 
change to MOD GC LOW HMR with a mass of 0.9 to (0.768, 0.804). Finally, after 
changing the sequencing read to MOD GC LOW HMR with a higher belief of 0.9, 
our ML prediction becomes significantly more reliable, resulting in an increase in 
the evidential interval to (0.768, 0.804). 
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Thus, after performing these experiments by changing the propositions and masses 
assigned to them, the evidential reasoning model behaves as per expectations and 
produces satisfactory results. Basic knowledge between the relationships of the input 
factors is needed for verification of the behavior of the model based on the 
experiment conducted. 
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CONCLUSION AND DISCUSSION 
 
The machine learning classifier used in this project is an improved version of the 
previous study where the data related to all the projects in the NIH GDC portal is 
considered ensuring the variability and heterogeneity of data. Although the previous 
research by Sharghi reported an SVC prediction accuracy of ~91%, it was achieved 
without considering the genes and mutations across to all the cancer projects which 
are a part of the GDC portal. Further, the previous study did not consider the lethality 
of every mutation. It was trained on a limited dataset of gene-mutation combinations 
which occurred in only 185 cases of the TCGA-PAAD project.  
The present study attempts to overcome these limitations by considering the 
genomic data with a high ‘VEP’ impact across all the cancer projects on GDC portal. 
Results achieved in this study have greater fidelity despite a lower prediction 
accuracy than what Sharghi's model achieved. The model is also very stable as it has 
a very low standard deviation. Thus, consideration of the most lethal and more 
extensive genomic data makes this model a better version of previous research. 
Further, based on given inputs, the observed results of the evidential model altered 
as per the expectations. The experiments conducted presented a positive hope that 
the evidential model can be used as an effective tool in the early detection of 
pancreatic cancer. Factors such as accessibility to real sequencing data, accurate 
family and personal history, along with more powerful and accurate NGS technology 
are crucial in confirming the feasibility of this approach. An amalgamation of an 
evidential reasoning approach with machine learning can prove to be a potential 
solution in early diagnosis of pancreatic cancer. 
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FUTURE WORK 
Scope of this project included sequencing of DNA from real pancreatic tissue in the 
Evidential Reasoning Model. Unfortunately, the unexpected circumstances 
prevalent due to COVID-19 prevented acquiring real pancreatic cancer sequence 
data from the California State University (CSU) East Bay Campus. Even though 
the NIH Cancer database has protected real pancreatic cancer sequence data, present 
COVID-19 circumstances has reduced their operational staff and has suspended 
processing applications to obtain access to such sequence data. Thus, the future 
scope of this project includes gathering the real sequencing data and incorporating it 
in the developed evidential reasoning model. The source of the genomic data for this 
project was The Cancer Genome Atlas Program (TCGA) which, even though being 
a reliable source, has a limited database of 185 cases in the pancreatic 
adenocarcinoma project. Hence, in order to improve the efficiency of the machine 
learning classifier, it is desirable to seek other authentic sources to gather real 
pancreatic cancer data. There is imbalance in the data currently being considered as 
cases related to pancreatic cancer constitute a small proportion in the overall dataset 
evaluated as opposed to non-pancreatic cancer records. Even though this project 
considers sampling of the records and assigning ‘class weight’ to the model to handle 
this imbalance, the model still overfits to a certain degree. Thus, the next phase of 
the project should concentrate on removing the imbalance in the data. The SVC was 
used as it traditionally has a good accuracy record. Future work may involve 
exploring other machine learning algorithms. Moreover, to improve the evidential 
reasoning model, the information related to the verified type of NGS technology 
should be used to access genetic data. Along with the real sequencing data, efforts 
should be made to acquire the real personal and family medical history along with 
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the smoking and drinking history of individuals in order to enhance the evidential 
reasoning model.   
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Appendix A 
 
PDAC originates in the ducts of pancreas, meaning that the cells present in the small 
tubes which line the periphery of pancreas undergo abnormal growth, leading to 
pancreatic cancer of this type. More precisely, the DNA in these cells undergo 
mutations causing the anomalous proliferation of the ductal cells which is 
uncontrollable. S. Amin and C. J. DiMaio describe the pathology of pancreatic 
adenocarcinoma as the cancer characterized by solid and firm tumors that are highly 
infiltrative (Amin & DiMaio, 2016). This study also mentions that this tumor invades 
beyond the main tumor before its diagnosis and thus, the cancer spreads outside of 
pancreas.  
The potential causes or risk factors of pancreatic cancer are broadly classified into 
‘Environmental’ and ‘Inherited’ (Gharibi, Adamian, & Kelber, 2016). Frequent 
cigarette smoking and alcohol can be environmental major risk factors. Pancreatic 
cancer is observed five to six times more frequently with individuals having a high 
smoking history (Pandol, Apte, Wilson, Gukovskaya, & Edderkaoui, 2012). 
Individuals with strong drinking history are reported to be prone to develop 
pancreatic cancer with an elevated risk up to1.5 to 6-fold than the individuals with 
no drinking history (Gupta, Wang, Holly, & Bracci, 2010).  Diabetes mellitus and 
elevated Body-Mass Index (BMI) may also be a potential cause of pancreatic cancer.  
In case of inherited factors, Familial Pancreatic Cancer (FPC), a condition in which 
at least two first-degree family members have pancreatic cancer may lead a person 
to develop this disease. Other hereditary factors include Lynch syndrome, Peutz–
Jeghers syndrome (PJS), hereditary breast-ovarian cancer, Familial atypical multiple 
mole melanoma (FAMMM), and Familial adenomatous polyposis (FAP) which 
create a great probability that a person may develop pancreatic cancer having any of 
these conditions inherited or in his / her family history. In addition, available options 
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to treat the PDAC are radiation therapy, chemotherapy, removing the tumor by 
surgery, or more than one of these techniques in combination (Gharibi, Adamian, & 
Kelber, 2016). 
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Appendix B 
Visualization techniques such as computer tomography (CT) and magnetic 
resonance imaging (MRI) are primarily used as the initial steps in pancreatic cancer 
evaluation after patients start showing symptoms. These techniques are commonly 
known as ultrasonography imaging of the abdomen. Some of the other visualization 
methods are magnetic resonance cholangiopancreatography (MRCP), or endoscopic 
ultrasound (EUS) used with CT and MRI. As per a study, EUS and fine-needle 
aspiration (FNA) biopsy of the mass is mostly undergone by patients as EUS is 
highly accurate while detecting small tumors of <=2 cm and focal lesions (De La 
Cruz, Young, & Ruffin, 2014). EUS is specially known for detecting tumors less 
than 10 mm with a sensitivity of 84% to detect 25 small tumors of 10mm coupled 
with a case where EUS-FNA was used to detect masses with a size less than 10mm 
in 23 patients had an accuracy of 96% (Hijioka, et al., 2017). However, detection of 
cancer should be before the visualization of pancreatic masses is possible even 
though visualization is a powerful aid in diagnosing pancreatic masses in order for 
a longer 5-year survival rate. 
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Appendix C 
Sequencing is the method to determine the sequence of nucleotide bases of genome 
or exome which can be performed on DNA or RNA (Gharibi, Adamian, & Kelber, 
2016). Sequencing has enabled researchers to distinguish between normal and 
abnormal tissues by analyzing he nucleotide bases of genomic and transcriptomic 
variations, thus assisting in identification of cancerous tissues (Sharghi, 2019). Next-
Generation Sequencing (NGS) is the terminology for contemporary sequencing 
technologies.  
As compared with digital polymerase chain reaction (PCR) method, detection of the 
CTCs using NGS techniques seems to be less sensitive. Analysis of ctDNA / ctRNA 
is better done with sequencing with high coverage. Sequencing data is also affected 
by attributes of the NGS technique used such as read length, depth of coverage, etc. 
It plays a major role in defining the accuracy and precision of the data which is to 
be sequenced. A large volume of chromosome loci can be evaluated using NGS. 
There are some disadvantages when using whole exome sequencing (WES). 
Identifying copy number alteration (CNA) can be negatively impacted by WGS 
methods. It is challenging to identify noncoding variants and rearrangements 
affecting gene regulation when whole exome sequencing (WES) is used over WGS 
(Wesley L. , 2019). Court et al. found out an ADO (allele drop out) rate of 85% and 
the reason behind the failure of most sequencing cases to be WGA (Court, et al., 
2016). 
Illumina is another powerful sequencing technology known for its highly accurate 
and precise throughput (Sharghi, 2019). Even though Illumina is known to have 
biases along with 1-2% error rate, it is believed to be used 90% of the times while 
sequencing. Erroneous results are accountable to reasons such as crosstalk, phasing, 
fading, and T accumulation, where substitution errors lead over insertion/deletion 
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errors (Heydari, Miclotte, Van de Peer, & Fostier, 2019). Biases include 
concentrated errors towards ends of DNA reads, whereas substitution errors happen 
with incorrect detection of a base near the end of a sequence. Homopolymer errors 
are commonly occur in the site of true polymorphism regions along with a case 
resulting in reoccurrence of same nucleotide. It is necessary to reduce the sensitivity 
of technology if these errors are to be minimized (Yeo, et al., 2012). While 
comparing sequencing technologies, it was observed that Illumina sequencing 
produced errors in the analysis of long polymers > 20 bases, whereas IonTorrent 
sequencing methodology could not accurately predict bases in homopolymers > 8 
bases nor could it read homopolymer regions > 14 bases (Quail, et al., 2012).  
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Appendix D 
Each mutation impacts the protein differently. As per the NIH GDC portal, every 
variant impacts the mutated protein in a certain way. The nature of its impact is 
observed and is distinguished based on its effect on the protein. The impact 
associated with the mutation is categorized into VEP, PolyPhen, and SIFT. The 
scope of this project is limited to the VEP category. The VEP impact is the effect on 
the structure and the behavior of protein. It is further classified into 4 sub-categories 
which are high, medium, low, and modifier. High VEP impact indicates that the 
variant disrupts the protein in a way such that the protein may undergo truncation, 
decay, or function loss. A moderate impact means that the variant may change the 
protein effectiveness in a non-disruptive manner. On the other hand, low impact may 
not change behavior of the protein and is harmless. Lastly, a modifier impact relates 
to the non-coding variants, that do not leave any evidence of impact by modifying 
non-coding genes.  
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Appendix E 
The machine learning classifier was developed to classify the mutations leading to 
pancreatic cancer from other cancerous mutations. An SVC was trained on the data 
from GDC portal. Different factors such as the gene, genetic mutation in that gene, 
the project (or the disease) in which its occurrence is observed along with the impact 
of the variant on the affected genome were considered. The data was taken for all 
the genes that are available on the GDC portal which resulted into about 2.8 million 
records. The records with the value ‘TCGA-PAAD’ in the project column were the 
targets with value ‘1’ whereas the records with any other project were labelled as 
‘0’. To obtain this data, a program was built which initially queried all the genes in 
the GDC portal. For every gene, the module queried GDC data portal for all 
mutations associated with the specified gene. With every mutation, the project in 
which it occurred was also associated. Every mutation impacts the genome 
differently, this data is also captured in the portal. Impact is categorized into ‘VEP 
impact’, ‘SIFT impact’, and ‘PolyPhen impact’ and this dataset only considers 
‘VEP’ impact of the genetic mutation. (See Appendix D for more details on the 
impact field.) A script was developed to compute the VEP impact for each record. 
Since the data size was extremely huge, there was a need to consider only the data 
which was more credible to avoid consideration of data which added little value to 
the set of highly impactful mutations. Hence, the dataset was sorted as per the project 
the mutation was found in, based on its impact, and finally based on the genes. Out 
of the sorted dataset, 5% of data from each project was considered in the final dataset 
which ensured all the highly impactful records from every project were considered. 
This technique ensured heterogeneity of the data and focus on the mutations with 
either high, or moderate impact. In this dataset, there was an imbalance as the records 
belonging to all other projects were way more than the ones belonging to pancreatic 
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cancer project. The model was built by using the support vector classifier with the 
‘rbf’ kernel, and the class_weight parameter equal to ‘balanced’. To measure the 
variance, a cross validation of 10 folds and 3 splits was applied. Since there was a 
large difference in the proportion of pancreatic cancer records and non-pancreatic 
cancer records, the imbalance in the data led to overfitting of the model. To balance 
the data, 2% records from every project and all the records belonging to TCGA-
PAAD project were considered as the final dataset and the same class classifier was 
trained on it. L2 penalty or Ridge regularization was further used to evaluate the 
overfitting. The data distribution of the final dataset considered is shown in the 
Figure 6. The data selected was found to be normally distributed. 
 
Figure 6. Distribution of the final dataset 
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Appendix F 
The evidential reasoning model consists of various input features such as ML 
prediction, smoking history, medical history, drinking history, biopsy site, NGS 
technology used, etc. Every input feature is considered as a frame and for every 
frame has certain possibilities which are called as propositions. A frame is created 
for every factor and saved in a text file called gallery_input by defining its name, 
propositions, its data type such as continuous or discrete, the original frame called 
as parent frame which is the source of origin of the current frame, the frame in which 
the current frame will merges into called as the result frame, and lastly the 
compatibility relations of the frame with other propositions. Each proposition is 
assigned a certain mass which are all stored in a mass distribution file. To lessen the 
impact of certainty or credibility in the belief of a frame, a discount is assigned to 
every frame which is also stored in a text file. Using Dempster’s Rule, the frames 
undergo fusion to form a new body of evidence which can be further used for fusing 
with other bodies of evidence (Yager, Liu, Dempster, & Shafter, 2008). The final 
output is computed and displayed as an interval of evidence which designates the 
level of belief in the propositions which are provided as input scenarios. This is a 
result of propagation of fused frames which transfuses from start to the end frame. 
